ROCKVILLE, Md., Feb. 12 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that James Sasser, former Senator (D-Tennessee) and former Ambassador to the People's Republic of China, has joined the Neuralstem Advisory Board and will serve as senior advisor on China.
Senator Sasser was elected to the United States Senate from Tennessee in 1976 where he served for eighteen years. During that time, Senator Sasser served as Chairman of the Senate Budget Committee as well as Chairman of various subcommittees on the Appropriations Committee, the Banking Committee and the Governmental Affairs committee. In 1995, Senator Sasser was appointed a Fellow at the Kennedy School at
"We are extremely proud and excited to have Senator Sasser come on board," said Neuralstem President & CEO Richard Garr. "The company is deeply committed to developing and commercializing our cell therapies in China. Senator Sasser brings an unmatched wealth of knowledge and experience with both the Chinese business and government communities." Neuralstem is in talks with leading medical facilities in China, where the company intends to target spinal cord injury.
"I am excited to help Neuralstem move forward in China," said Senator Sasser. "This new technology is a leading example of American innovation, and has the potential to help so many people all over the world. I am looking forward to being a part of that."
Senator Sasser also serves on the Board of Trustees of the National Geographic Society, on the Board of the Elliott School of International Relations at
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.
In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended September 30, 2008.
|SOURCE Neuralstem, Inc.|
Copyright©2009 PR Newswire.
All rights reserved